Recent advances in non-surgical treatment for advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers and is the leading cause of cancer death in Taiwan. Curative surgery is feasible for only about 30% of patients. Transarterial embolization or chemoembolization (TAE/TACE) has been demonstrated to provide a survival benefit compared with supportive care for HCC patients with adequate liver reserves, tumors confined to the liver, and no evidence of portal vein thrombosis. Percutaneous ethanol injection (PEI) may provide long-term disease control if the extent of liver tumors is limited (3 or less in number and less than 3 cm in diameter). The relative efficacy of TAE/TACE, PEI, and other locoregional treatment modalities, such as radiofrequency ablation or cryosurgery, remains unclear, Radiotherapy has been used mostly as a salvage therapy in combination With other locoregional modalities. Despite the incorporation of 3-dimensional conformal technology, radiation-induced liver injury remains an important problem, especially for patients with hepatitis B-related cirrhosis. Systemic therapy is difficult for HCC because,of the underlying cirrhosis and accompanying hypersplenism and peripheral cytopenia. HCC is typically-resistant to most cytotoxic agents. Biochemical modulation with high-dose tamoxifen may sensitize HCC cells to doxorubicin-induced apoptosis and improve the clinical response to doxorubicin in patients,with advanced HCC. Thalidomide, which inhibits, angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor, can produce a response in some HCC. patients. Future research on drug therapy for HCC will focus on identification tumor-specific targets.